treatment-resistant depression
Mental health · 2021–2024
4decisions
1medicine
4carried consumer input
84individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| esketamine Treatment of treatment-resistant depression (major depressive disorder) in adults who have not responded adequately to at least two separate courses of… | Dec 2024 | Recommended with restriction | 2 individuals |
| esketamine Treatment of treatment-resistant depression (TRD) in adult patients with major depressive disorder who have not responded adequately to at least 2 separate… | Jul 2023 | Not recommended | 58 individuals |
| esketamine Treatment resistant depression (TRD) in adult patients with major depressive disorder who have not responded adequately to at least two separate courses of… | Jul 2022 | Not recommended | 22 individuals Lived Experience Australia · Samy Medical Group |
| esketamine Treatment resistant depression (TRD) in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration, to be… | Jul 2021 | Not recommended | 2 individuals |
Who spoke
Lived Experience Australia · Samy Medical Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.